Risk vs Benefit in Diabetes Pharmacotherapy: a Rational Approach to Choosing Pharmacotherapy in Type 2 Diabetes

被引：0
作者：
Mary Elizabeth Cox
Mark N. Feinglos
机构：
[1] Medical Clinic of North Texas,
[2] Duke University Medical Center,undefined
来源：
Current Diabetes Reports | 2013年 / 13卷
关键词：
Type 2 diabetes; Pharmacotherapy; Metformin; Sulfonylurea; Pioglitazone; Dipeptidyl peptidase-4 inhibitor; Glucagon-like-peptide-1 receptor agonist; Insulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Type 2 diabetes now affects more than 1 in 10 US adults and is a leading cause of morbidity, mortality, and healthcare expense. There are increasing numbers of available pharmacotherapies, with established agents as well as newer drugs developed from hormones in the incretin pathway, among others. New data are accumulating continuously with respect to potential benefits of both long-standing and new agents, as well as risks identified through post-marketing surveillance. Here we review the commonly prescribed pharmacotherapy options with attention to recently published information and provide a rational approach to choice of therapy.
引用
收藏
页码：319 / 328
页数：9
相关论文
共 247 条
  • [1] Wang YC(2011)Health and economic burden of the projected obesity trends in the USA and the UK Lancet 378 815-825
  • [2] McPherson K(2007)Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457-2471
  • [3] Marsh T(2011)Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Ann Intern Med 154 602-613
  • [4] Gortmaker SL(2009)Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 193-203
  • [5] Brown M(2012)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the study of diabetes (EASD) Diabetes Care 35 1364-1379
  • [6] Nissen SE(2012)Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians Ann Intern Med 156 218-231
  • [7] Wolski K(2009)Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetologia 52 17-30
  • [8] Bennett WL(1997)A strategy for arterial risk assessment and management in type 2 (non-insulin-dependent) diabetes mellitus Diabet Med 14 611-21
  • [9] Maruthur NM(2000)Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 405-412
  • [10] Singh S(2008)Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2545-59
12345678910